Journal of Pharmacokinetics and Pharmacodynamics

, Volume 40, Issue 3, pp 369–376

Disease progression and neuroscience

Authors

    • Department of Pharmacology & Clinical PharmacologyUniversity of Auckland
Review Paper

DOI: 10.1007/s10928-013-9316-2

Cite this article as:
Holford, N. J Pharmacokinet Pharmacodyn (2013) 40: 369. doi:10.1007/s10928-013-9316-2

Abstract

The concepts of disease progression are discussed in the context of neurological disorders. The importance of understanding the time course of the response to inactive (placebo) treatment is discussed. Disease progression and response to placebo treatment both need to be considered before drug effects can be reliably identified. Criteria for distinguishing between symptomatic and disease modifying drug effects are proposed and used to interpret the results of clinical trials in pain, depression, schizophrenia, stroke, Alzheimer’s disease and Parkinson’s disease.

Keywords

Disease progressionNeuroprotectionDisease modifyingNeuroscienceAlzheimer’sParkinson’s

Copyright information

© Springer Science+Business Media New York 2013